Growth Hormone Treatment in Adult Patients With Chronic Kidney Disease

Novo Nordisk A/S140 enrolled

Overview

This trial is conducted in Asia, Europe, and Middle East. Adult patients with chronic kidney disease are treated with growth hormone to assess effect on nutritional status.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

140

Conditions

Chronic Kidney Disease End-Stage Renal Disease

Interventions

somatropinDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 99 Years

Medical Language ↔ Plain English

Inclusion Criteria: * ESRD patients Exclusion Criteria: * Diabetes Mellitus * Severe and Malignant diseases * Patients in Intensive Care Units

Locations (26)

Novo Nordisk Investigational Site

Århus N, Denmark

Outcomes

Primary Outcomes

Change in surrogate markers of nutrition

Time frame: After 6 months treatment

Secondary Outcomes

Quality of Life

Other markers of nutrition

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.